PROTAC SOS1 degrader-1 (TFA)

• UNSPSC Description:

  PROTAC SOS1 degrader-1 (TFA) is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity[1].

• Target Antigen:

  PROTACs; Ras

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;MAPK/ERK Pathway;PROTAC

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-sos1-degrader-1-tfa.html

• Solubility:

  10 mM in DMSO|DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1N(C([C@@H](NC(CCCCCCCCN2CCN(C3=C4C(N(CC5=CC(C)=C(F)C(C)=C5)C(N6CC7(CNC7)C6)=N4)=CC(Cl)=C3)CC2)=O)C(C)(C)C)=O)C[C@H](O)C1)N[C@H](C8=CC=C(C9=C(C)N=CS9)C=C8)C.OC(C(F)(F)F)=O

• Molecular Weight:

  1165.82

• References & Citations:

  [1]Zhou C, et al. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations. J Med Chem. 2022 Mar 10;65(5):3923-3942.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported